Gurgaon, India, July 14, 2008:
In view of media reports emanating over the weekend, Ranbaxy would like to clarify its position and put things in the correct perspective.
Ranbaxy strongly denies the allegations contained in the Motion that has been filed (Not Granted) by the US Department of Justice (DOJ), seeking certain documents. No legal proceedings in the sense of a prosecution have been initiated. The Company continues to cooperate with the DOJ in regards to the investigation and has agreed to produce the specific documents sought by the Motion.
Ranbaxy will be filing a response today in the US District Court for The District of Maryland and will strongly defend its position.
The Company would like to state that an investigation has been underway for approximately three years and no charges have been filed against the Company. The FDA has also gathered over 200 random samples of various products marketed by the company in the US. These products have been independently tested by the USFDA and were found to be complying with all the specifications.
Under these circumstances the company finds that the allegations are baseless.
The Company's business in the US continues as normal. Ranbaxy remains committed to providing high quality generic medicines at affordable prices to its customers and patients in the United States.
Ranbaxy also clarifies that the Company's deal with Daiichi Sankyo is binding and final and remains on track.
Ranbaxy Laboratories Limited, India 's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.